Smith & Nephew has inked a co-marketing deal with OrthoSensor involving one of the company's orthopedic surgical tools. Neither side is discussing financial details.
A little biotech startup with an impressive lineup of biotech veterans among its backers has won over pharma giant Johnson & Johnson as an early partner on its plan to develop a new drug for Alzheimer's, currently one of the toughest targets in the drug business.
In the midst of rethinking its approach to R&D, AstraZeneca has dabbled in the virtual model of drug development, matching a small in-house staff with collaborators on contractors around the globe to make the process more efficient. Now, after some early success in neuroscience, the pharma giant is amping up its virtual efforts in oncology, signing a deal with a South Korean institution to hunt for new targets in the field.
Indiana's Harlan Laboratories has struck up a deal with French CRO Bertin Pharma to pool resources on early development, teaming up to offer drug discovery and translational medicine services.
BSD Medical said Terumo will distribute one of its key ablation surgical tools into Eastern European markets and the Middle East over the coming months, expanding on a fledgling partnership that has already demonstrated some traction in other European, Western Asian and African countries.
CRO Charles River Laboratories has selected Exostar to serve as the gatekeeper to its data, tasking the cloud-based service provider with securing its proprietary information.
Medtronic and Abbott have collaborated on a discount deal that makes the two stent giants preferred vendors for the costly medical devices at 135 U.S. hospitals.
Netherlands' CRO Cardialysis has reached out to Boston eClinical outfit AG Mednet to oversee data submission and collection for the medical device and drug trials it runs at more than 1200 sites around the world.
Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. Late last week the Belgian biotech reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect.
MPI Research and its CRO partners are a couple months away from cutting the ribbon on their imaging-focused collaboration, and now the three have installed the particle accelerator they say they'll need to stand out among other drug researchers.